New evidence suggests genetics—not geography—may explain why Leqembi causes fewer ARIA brain side effects in parts of Asia, and what that means for families everywhere.
Alzheimer’s treatment eligibility may be far larger than previously thought. A major Nature study using blood tests suggests millions more older adults could qualify for treatment than current use reflects. As diagnosis becomes easier, demand for drugs like Leqembi could shift sharply.
New studies highlight smoother tolerability, easier routines, and practical safety updates that make the rivastigmine patch an increasingly caregiver-friendly option.
Three major GLP-1 trials came out in late 2025. One weight-loss drug slowed early Alzheimer’s decline, while two others failed. Surprisingly, this mixed pattern may point the way toward a promising new treatment direction.
New long-term data suggests lecanemab could delay the shift from mild memory loss to moderate Alzheimer’s by up to eight years—offering families precious time and renewed hope.
Leqembi is one of the first Alzheimer’s treatments proven to slow decline. A new MRI study helps explain what it can—and cannot—do in the brain’s early months, offering clearer expectations for caregivers.
NEW RESEARCH: A diabetes medication already helping millions, called Jardiance, improves memory, strengthens blood flow, and supports overall brain health in pre- and early Alzheimer’s.
Some everyday medicines may nudge dementia risk higher — but safer, equally effective alternatives often exist. Here’s how to replace high-risk drugs with brain-friendlier options
IMAGINE THIS: Instead of going to an infusion center for treatment, you can switch to a weekly injection at home. That’s now a reality for many Alzheimer’s patients.
Caring for someone with Alzheimer’s is demanding enough. Now, instead of traveling for hours of infusions, families can turn to Leqembi IQLIK—a once-weekly injection approved by the FDA that makes treatment simpler, safer, and closer to home.
The “glymphatic system” removes brain waste. It may be a powerful new target to treat Alzheimer’s. Learn why scientists believe Alzheimer’s may arise when the system is not doing its cleaning properly.
Plaques are the best-known Alzheimer’s culprit. Cambridge scientists have figured out the 7 steps to forming these plaques. Find out how targeting the formation of these “oligomers” may hold the key to a cure.
UCLA researchers found active people build 5% more gray matter in their brain. See how this prevents Alzheimer’s.
The “glymphatic system” removes brain waste. It may be a powerful new target to treat Alzheimer’s. Learn why scientists believe Alzheimer’s may arise when the system is not doing its cleaning properly.
Plaques are the best-known Alzheimer’s culprit. Cambridge scientists have figured out the 7 steps to forming these plaques. Find out how targeting the formation of these “oligomers” may hold the key to a cure.
UCLA researchers found active people build 5% more gray matter in their brain. See how this prevents Alzheimer’s.
Learn about The Alzheimer’s Society of Canada’s campaign to bust the stigma of dementia.
Discover 6 easy ways you can make a difference.
No spam, only news and updates.
